AU2010262952B2 - Biomarker assay of neurological condition - Google Patents

Biomarker assay of neurological condition Download PDF

Info

Publication number
AU2010262952B2
AU2010262952B2 AU2010262952A AU2010262952A AU2010262952B2 AU 2010262952 B2 AU2010262952 B2 AU 2010262952B2 AU 2010262952 A AU2010262952 A AU 2010262952A AU 2010262952 A AU2010262952 A AU 2010262952A AU 2010262952 B2 AU2010262952 B2 AU 2010262952B2
Authority
AU
Australia
Prior art keywords
biomarker
injury
levels
subject
gfap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010262952A
Other languages
English (en)
Other versions
AU2010262952A1 (en
Inventor
Stephen Frank Larner
Juan Martinis
Stanislav I. Svetlov
Kevin Ka-Wang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Banyan Biomarkers Inc
Original Assignee
Banyan Biomarkers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyan Biomarkers Inc filed Critical Banyan Biomarkers Inc
Publication of AU2010262952A1 publication Critical patent/AU2010262952A1/en
Application granted granted Critical
Publication of AU2010262952B2 publication Critical patent/AU2010262952B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010262952A 2009-06-19 2010-06-21 Biomarker assay of neurological condition Active AU2010262952B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21872709P 2009-06-19 2009-06-19
US61/218,727 2009-06-19
US34518810P 2010-05-17 2010-05-17
US61/345,188 2010-05-17
PCT/US2010/039335 WO2010148391A2 (en) 2009-06-19 2010-06-21 Biomarker assay of neurological condition

Publications (2)

Publication Number Publication Date
AU2010262952A1 AU2010262952A1 (en) 2012-01-19
AU2010262952B2 true AU2010262952B2 (en) 2016-01-07

Family

ID=43357089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010262952A Active AU2010262952B2 (en) 2009-06-19 2010-06-21 Biomarker assay of neurological condition

Country Status (6)

Country Link
US (2) US20130029859A1 (https=)
EP (2) EP3355059A3 (https=)
JP (3) JP5875514B2 (https=)
AU (1) AU2010262952B2 (https=)
CA (1) CA2766057A1 (https=)
WO (1) WO2010148391A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
WO2012141674A2 (en) 2010-01-26 2012-10-18 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
JP2013524220A (ja) * 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
US20170023591A1 (en) * 2014-04-07 2017-01-26 Iron Horse Diagnostics, Inc. Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems
WO2016055148A2 (en) * 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury
JP2018510359A (ja) 2015-02-05 2018-04-12 イミューンアレイ ユーエスエイ インコーポレイテッド 脳損傷または神経変性を診断するための方法および組成物
CN107864671A (zh) 2015-05-05 2018-03-30 加利福尼亚大学董事会 星形细胞创伤节和神经创伤生物标志物
EP3479121A4 (en) * 2016-06-30 2020-03-11 Brainbox Solutions, Inc. CONCENTRATIONS OF CIRCULATING BIOMARKERS FOR DIAGNOSIS AND RISK STRATIFICATION OF SKULL BRAIN TRAUMATA
JP2019535015A (ja) * 2016-10-03 2019-12-05 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
CN106568750B (zh) * 2016-10-31 2019-12-03 陕西脉元生物科技有限公司 一种基于荧光能量共振转移法的gfap检测方法
EP3602069A1 (en) * 2017-03-23 2020-02-05 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
BR112019021612A2 (pt) 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
US10877038B2 (en) 2017-04-28 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2018217792A1 (en) 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
JP7416625B2 (ja) 2017-05-25 2024-01-17 アボット・ラボラトリーズ 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
BR112019025313A2 (pt) 2017-05-30 2020-06-23 Abbott Laboratories Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
CA3084064A1 (en) * 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
EP4465051A3 (en) * 2018-05-29 2025-01-22 Cognizance Biomarkers, Inc. Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures
KR102072563B1 (ko) * 2018-06-27 2020-02-03 가톨릭대학교 산학협력단 Dpysl2를 포함하는 인터넷 게임 장애 진단용 바이오마커 및 그의 용도
EP4081804A1 (en) * 2019-12-23 2022-11-02 Albert-Ludwigs-Universität Freiburg Gut microbiota-related methods for treating dementia and age-dependent cognitive decline
KR102464243B1 (ko) * 2020-04-01 2022-11-08 프리시젼바이오 주식회사 외상성 뇌손상 바이오마커 검출용 시분해 형광분석 측방유동 분석장치 및 이를 이용한 외상성 뇌손상 바이오마커 측정방법
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用
KR102759445B1 (ko) * 2021-11-16 2025-01-24 한국한의학연구원 치료에 따른 보행 장애 개선 판별용 바이오마커 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019553A2 (en) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
WO2003032894A2 (en) * 2001-10-12 2003-04-24 Pfizer Products Inc. Method of monitoring neuroprotective treatment
CA2498614C (en) * 2002-09-11 2013-04-16 University Of Florida Analyzing nerve cell damage
DK2357477T3 (en) * 2003-09-20 2018-02-05 Electrophoretics Ltd Diagnostic approach for brain injury-related disorders based on detection of NDKA
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
EP2207033B1 (en) * 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
CA2668640A1 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
US8293489B2 (en) * 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
JP2009052933A (ja) * 2007-08-24 2009-03-12 Rakuno Gakuen プリオン病の検出方法及び診断キット
CN101983337A (zh) * 2008-02-04 2011-03-02 班扬生物标记公司 用于诊断或治疗脑损伤的方法
WO2011032155A2 (en) * 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019553A2 (en) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MISSLER, U. et al. Clinical Chemistry. 1999, vol. 45, pages 138-141 *
NYLEN, K. et al. Journal of Neurological Sciences. 2006, vol. 240, pages 85-91 *
PELINKA, L.E. et al The Journal of TRAUMA Injury, Infection, and Critical Care. 2004, vol. 57, pages 1006-1012 *
VOS, P.E. et al. Neurology. 2004, vol. 62, pages 1303-1310 *
ZHU, L. et al. Neuroscience Letters. 2004, vol. 367, pages 210-212 *

Also Published As

Publication number Publication date
JP2017125853A (ja) 2017-07-20
JP2012530907A (ja) 2012-12-06
AU2010262952A1 (en) 2012-01-19
EP3355059A2 (en) 2018-08-01
EP2443461A2 (en) 2012-04-25
EP2443461A4 (en) 2012-12-26
JP2015172587A (ja) 2015-10-01
US20190064187A1 (en) 2019-02-28
CA2766057A1 (en) 2010-12-23
JP5875514B2 (ja) 2016-03-02
WO2010148391A2 (en) 2010-12-23
US20130029859A1 (en) 2013-01-31
JP6408041B2 (ja) 2018-10-17
EP3355059A3 (en) 2018-09-26
WO2010148391A3 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
AU2010262952B2 (en) Biomarker assay of neurological condition
US20150268252A1 (en) Biomarker assay of neurological condition
US11994522B2 (en) Biomarker detection process and assay of neurological condition
US20120202231A1 (en) Synergistic biomarker assay of neurological condition using s-100b
AU2011235892B2 (en) Markers and assays for detection of neurotoxicity
EP3115785A2 (en) Process to diagnose or treat brain injury
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
US12601749B2 (en) Biomarker detection process and assay of neurological condition
AU2015203660A1 (en) Process to diagnose or treat brain injury

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)